Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2000

View Archived Issues

Myogen issued patent for heart failure combination

Organogenesis receives milestone payment related to Apligraf progress

Clinical trial of STR in Ewing's sarcoma initiated by NeoRx

Antagonists of alcohol's harmful effects in nerve cells discovered

Barr and DuPont mount development and marketing venture

Immunostimulatory sequence designed by Dynavax reduces HSV-2 severity

Vanguard Medical signs collaboration with WIBR for CNS disorders

Consensus receives SBIR grant to develop new class of HIV inhibitors

HPV vaccine alliance established by MediGene and Schering AG

Preliminary results from pivotal trial of Uniprost promising

ICAgen and Yamanouchi to develop novel CNS therapeutics

Agents for thrombocytopenia discovered at Kyowa Hakko

Sankyo presents newest antifungal triazoles

Potent antistaphylococcal activity exerted by Sankyo's new carbapenems

Novel antiviral agents in development at ViroPharma for Flaviviridae infections

Pfizer claims NSAIDs linked to NO-releasing moiety associated with reduced GI toxicity

Repligen initiates largest-ever study in autism

Novel peptides and their use in the treatment of diabetes reported by Amylin

Study indicates functional abnormalities in children with ADHD

ACS news: subtype-selective NMDA receptor antagonists with potential in PD

Benzimidazole inhibitors of V-ATPase designed at Fujisawa for osteoporosis Rx

SAR for beta-turn mimetics of enkephalin discussed at ACS by Molecumetics

Inhibitors of cdk2 pursued by CV Therapeutics for use in restenosis

HMR-1556 selected for further evaluation as antiarrhythmic agent, presented to ACS

AltaRex presents clinical plan for OvaRex at BIO 2000 annual meeting

KT3-671 beneficial in diabetic nephropathy according to recent preclinical results

SmithKline Beecham claims 5-HT6 antagonists for ADHD

Hemodynamic effects of AH-1058 evaluated by telemetry in dogs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...